AstraZeneca Shares Fall on Merger Doubts with Bristol Myers Squibb

Key facts

• AstraZeneca's stock price fell 6%.
• AstraZeneca's stock price reached 11,866p.
• Investors are skeptical about a potential merger between AstraZeneca and Bristol Myers Squibb.
• The potential merger is valued at $400 billion.
• Concerns include the deal's impact on AstraZeneca's UK listing.
• Concerns include potential antitrust issues.
• The stock drop reflects investor apprehension about the merger's feasibility and implications.

AstraZeneca's share price experienced a significant decline, dropping 6% to 11,866p. This downturn is attributed to investor skepticism surrounding a potential $400 billion merger with its U.S. rival, Bristol Myers Squibb. The apprehension among shareholders stems from several key concerns. Foremost among these is the potential impact such a merger could have on AstraZeneca's listing on the UK stock exchange. Additionally, there are significant worries about potential antitrust issues that could arise from combining two major pharmaceutical companies. The scale of the proposed deal, valued at $400 billion, amplifies these concerns, making investors cautious about the long-term implications and regulatory hurdles.